Skip to content

Nuvation Bio NUVB Intangible Assets Net Of Amortization

Intangible Assets Net Of Amortization at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$367.36M
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$38.95M-14.1%
Illumina logo
IlluminaILMN
$430M+54.7%
MaxLinear logo
MaxLinearMXL
$46.41M-10.0%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$4.55B+1.8%
Insmed logo
InsmedINSM
$95.57M+66.5%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:IntangibleAssetsNetOfAmortization.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's intangible assets net of amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's intangible assets net of amortization?
Nuvation Bio (NUVB) reported intangible assets net of amortization of $1.86M in Q4 2025.
What is the long-term trend for Nuvation Bio's intangible assets net of amortization?
Over 2 years (2023 to 2025), Nuvation Bio's intangible assets net of amortization has grown at a 103.5% compound annual growth rate (CAGR), from $448K to $1.86M.
What does intangible assets net of amortization mean?
This represents the carrying value of non-physical assets such as patents, intellectual property, or acquired licenses, net of accumulated amortization. For a biopharmaceutical company, this often captures the capitalized value of drug development pipelines or proprietary technology platforms. It is a key indicator of the long-term value embedded in the company's research and development efforts.